Tiziana Life Sciences PLC

Tiziana Life Sciences PLC Announces Development Plans for Foralumab & SAB Appointments - Seite 3

For more information go to http://www.tizianalifesciences.com

Forward-Looking Statements

Certain statements in this press release are forward-looking. These statements may be identified by the use of forward-looking words such as "anticipate," "planned," "believe," "forecast," "estimated," "expected," and "intend," among others. These forward-looking statements are based on Tiziana's current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, substantial competition; our need for additional financing; uncertainties of patent protection and litigation; uncertainties of government or third party payer reimbursement; limited sales and marketing efforts and dependence upon third parties; and risks related to failure to obtain FDA clearances or approvals and noncompliance with FDA regulations. As with any pharmaceutical under development, there are significant risks in the development, regulatory approval and commercialization of new products. There are no guarantees that future clinical trials discussed in this press release will be completed or successful or that any product will receive regulatory approval for any indication or prove to be commercially successful. While the list of factors presented here is considered representative, no such list should be considered to be a complete statement of all potential risks and uncertainties. Unlisted factors may present significant additional obstacles to the realization of forward-looking statements. Forward-looking statements included herein are made as of the date hereof, and Tiziana does not undertake any obligation to update publicly such statements to reflect subsequent events or circumstances.

All registered trademarks are owned by Tiziana Life Sciences.

Contacts

Tiziana Life Sciences PLC Gabriele Cerrone, Chairman and founder		[phone]
Cairn Financial Advisers LLP Nominated Adviser Liam Murray / Avi Robinson		[phone]
Beaufort Securities Limited Broker Saif Janjua		[phone]
FTI Consulting Limited Simon Conway / Rob Winder / Natalie Garland-Collins		[phone]

Source: Tiziana Life Sciences

This information is provided by RNS
The company news service from the London Stock Exchange

Contacts:
RNS
Customer
Services
0044-207797-4400
[e-mail]
http://www.rns.com